Industry supports generic substitution in England, but with some caveats
This article was originally published in Scrip
The UK R&D-based pharmaceutical industry says its support for the Department of Health's plans to introduce generic substitution in England hinges on four conditions.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.